RTP Mobile Logo
Oncology Nursing Update, Lung Cancer Edition, Issue 1, 2016
Released April 2016

Featuring interviews with Dr Sarah B Goldberg, Ms Ann Culkin, Dr Anne S Tsao and Dr Gary Deng. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Traditionally, chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes for patients with lung cancer. However, the advent of biologic agents and immunotherapies has led to recent improvements in disease-free and overall survival in select patient populations. Importantly, published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with lung cancer, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.

    PURPOSE STATEMENT
    To present the most current research developments and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of lung cancer.

    LEARNING OBJECTIVES

    • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including chemotherapy regimens, targeted biologic treatments and immunotherapeutic approaches.
    • Communicate the clinical relevance of gene mutations and tumor histology to patients with non-small cell lung cancer (NSCLC).
    • Educate patients receiving EGFR and ALK inhibitors about potential side effects, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
    • Develop an understanding of the mechanism of action, efficacy and safety/toxicities of anti-PD-1 checkpoint inhibitors to enable their appropriate integration into routine clinical practice.
    • Recognize the recent FDA approvals of ramucirumab and necitumumab, and discern how these agents can be safely administered to appropriate patients with squamous and nonsquamous disease.
    • Explore the role of integrative oncology approaches, including complementary and alternative therapies, in patient care.

    ACCREDITATION STATEMENT

    CNE credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CNE credit is no longer available for this issue

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    CNE credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is an audio CNE program.

    CNE credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Dr Deng has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr GoldbergAdvisory Committee: Clovis Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc. Ms CulkinAdvisory Committee: Novartis Pharmaceuticals Corporation, TESARO Inc. Dr TsaoAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update, Lung Cancer Edition, Issue 1, 2016
Released April 2016

Featuring interviews with Dr Sarah B Goldberg, Ms Ann Culkin, Dr Anne S Tsao and Dr Gary Deng. (Audio Content)

Read print: